Neurology

Developments in glycine transporter type 1 inhibitors, D-amino acid oxidase inhibitors, and phosphodiesterase inhibitors are pushing schizophrenia research forward.

Despite the positive results demonstrated in a prior phase 2 trial, AMX0035 failed to meet the phase 3 trial’s primary end point in treating patients with amyotrophic lateral sclerosis.

The recent ODD for the utidelone injectable could offer another treatment option for patients with BCBM.

Investigators found that mRNA technology for the delivery of antibody therapeutics were used to target tau in Alzheimer disease and can be applied to other tau targets.

The results displayed a dramatic reduction in the individuals’ tumors within days after single treatment.

Melatonin is linked to circadian rhythm, mitochondrial function, and neuroinflammation.

Zero relapses were reported among individuals that received ravulizumab-cwvz over the 73 weeks of treatment.

The FDA recommends the dosage of givinostat (Duvyzat; Italfarmaco, ITF Therapeutics) should be based on the individual’s body weight and administered twice daily with food.

The platform is a first-of-its-kind therapeutic approach to promote remyelination among individuals with relapsing/remitting multiple sclerosis.

The FDA is convening a committee to discuss phase 3 data after the planned action date, which delays drug availability to patients.

“I’m better than I was before I had long COVID, and in so many ways,” said a patient in an interview with Pharmacy Times.

If vorasidenib receives full approval, it would be a first-in-class target therapy to treat individuals with IDH-mutant gliomas.

Understanding differences in the various levodopa formulations and assisting with medication therapy management is a crucial role for pharmacists.

Monitoring metal ion concentrations and chelation therapy is hypothesized to alleviate symptoms and diseases caused by neuroinflammation.

Hospital pharmacists can play an important role in advocating for, designing, and implementing various policies to optimize care.

Adults diagnosed with coronary heart disease before age 45 have an especially increased risk of developing dementia, Alzheimer disease, and vascular dementia.

The pattern for the diminished learning curve, associated with elevated amyloid levels, was consistent across 3 memory tasks, with strongest results for recalling digit-signs and groceries prices.

Due to the observational nature of the study, the study authors said they cannot determine causal relationships between statins and cognitive decline for patients with Alzheimer disease.

From newsworthy moments to groundbreaking research, these were the most-read Alzheimer disease-related articles on Pharmacy Times in 2023.

Investigators analyzed the effects of harmful accumulation of HDAC6 in the brains of mouse models with Alzheimer disease to determine any changes in disease progression.

Improvements in PFS were also seen among patients with brain metastases.

Patients with this genetic variant have impaired neuronal excitability, a trait that has been linked to malfunctional synapses.

Following acoustic stimulation intervention, many patients experienced a reduction in neurobehavioral symptoms.

Drug reaction with eosinophilia and systemic symptoms can start as a rash and quickly progress, affecting the internal organs and requiring hospitalization, even resulting in death.

More studies are needed to show conclusive benefits on patient functionality.

Pharmacists can play a vital role in educating patients about headaches and can help to limit their impact on the patient.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

Pharmacists play a key role in optimizing drug therapy according to the most updated guidelines, educating patients or prescribers, and monitoring therapeutic outcomes.

A weekly dose of injectable lecanemab-irmb (Leqembi) could allow patients with Alzheimer disease to receive the drug at home instead of visiting an infusion center twice per month.

Lecanemab is a humanized immunoglobulin gamma 1 monoclonal antibody that targets amyloid plaques, which are thought to play a role in the development and progression of Alzheimer disease.